From Macrocirculation to Microcirculation: Benefits of Preterax

American Journal of Hypertension

Volumn 20, Issue 7 SUPPL., 2007, Pages

  Struijker Boudier, Harry A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

diabetes mellitus; hypertension; indapamide; Microcirculation; perindopril

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE PLUS PERINDOPRIL; PRETERAX; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTERIOLE; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY; CARDIOVASCULAR DISEASE; DETERIORATION; GLOMERULUS; HUMAN; HYALINE DEGENERATION; HYPERTENSION; KIDNEY FAILURE; KIDNEY TUBULE DAMAGE; MESANGIUM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULSE WAVE; REMISSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 34249305171     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.04.013     Document Type: Article

References (30)

1. Cohuet G., and Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 111 (2006) 81-98
2. Mourad J.J., Hanon O., Deverre J.R., Camici P.G., Sellier P., Duboc D., and Safar M.E. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 4 (2003) 94-95
3. Silvestre J.S., Kamsu-Kom N., Clergue M., Duriez M., and Levy B.I. Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther 303 (2002) 1038-1043
4. Rakusan K., Cicutti N., Maurin A., Guez D., and Schiavi P. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res 59 (2000) 243-254
5. Levy B.I., Duriez M., and Samuel J.L. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 14 (2001) 7-13
6. Renaud I.M., Chainey A., Belair M.F., Mandet C., Michel O., Myara I., Chevalier J., and Plante G.E. Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination. Fundam Clin Pharmacol 18 (2004) 437-447
7. Hayakawa H., Coffee K., and Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 96 (1997) 2407-2413
8. Hayakawa H., and Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 29 (1997) 235-241
9. Struijker Boudier H.A., Cohuet G.M., Baumann M., and Safar M.E. The heart, macrocirculation and microcirculation in hypertension: a unifying hypothesis. J Hypertens Suppl 21 (2003) S19-S23
10. Aoun S., Blacher J., Safar M.E., and Mourad J.J. Diabetes mellitus and renal failure: effects on large artery stiffness. J Hum Hypertens 15 (2001) 693-700
11. Taniwaki H., Nishizawa Y., Kawagishi T., Ishimura E., Emoto M., Okamura T., Okuno Y., and Morii H. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care 21 (1998) 1848-1855
12. Camici P.G., and Crea F. Coronary microvascular dysfunction. N Engl J Med 355 (2006) 61-71
13. Blacher J., Pannier B., Guerin A.P., Marchais S.J., Safar M.E., and London G.M. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32 (1998) 570-574
14. Scuteri A., Cacciafesta M., Di Bernardo M.G., De Propris A.M., Recchi D., Celli V., Cicconetti P., and Marigliano V. Pulsatile versus steady-state component of blood pressure in elderly females: an independent risk factor for cardiovascular disease?. J Hypertens 13 (1995) 185-191
15. Blacher J., Asmar R., Djane S., London G.M., and Safar M.E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33 (1999) 1111-1117
16. Madhavan S., Ooi W.L., Cohen H., and Alderman M.H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23 (1994) 395-401
17. Benetos A., Safar M., Rudnichi A., Smulyan H., Richard J.L., Ducimetieere P., and Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 30 (1997) 1410-1415
18. Blacher J., Staessen J.A., Girerd X., Gasowski J., Thijs L., Liu L., Wang J.G., Fagard R.H., and Safar M.E. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 160 (2000) 1085-1089
19. Franklin S.S., Larson M.G., Khan S.A., Wong N.D., Leip E.P., Kannel W.B., and Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging?. The Framingham Heart Study. Circulation 103 (2001) 1245-1249
20. Verdecchia P., Schillaci G., Reboldi G., Franklin S.S., and Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 103 (2001) 2579-2584
21. Millar J.A., Lever A.F., and Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 17 (1999) 1065-1072
22. Mitchell G.F., Moye L.A., Braunwald E., Rouleau J.L., Bernstein V., Geltman E.M., Flaker G.C., Pfeffer M.A., and SAVE investigators. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Survival and Ventricular Enlargement. Circulation 96 (1997) 4254-4260
23. Safar M.E., Blacher J., Pannier B., Guerin A.P., Marchais S.J., Guyonvarc'h P.M., and London G.M. Central pulse pressure and mortality in end-stage renal disease. Hypertension 39 (2002) 735-738
24. Schram M.T., Kostense P.J., Van Dijk R.A., Dekker J.M., Nijpels G., Bouter L.M., Heine R.J., and Stehouwer C.D. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 20 (2002) 1743-1751
25. Zoppini G., Verlato G., Zamboni C., Venturi C., Gennaro N., Biasi V., Bonora E., and Muggeo M. Pulse pressure and mortality from cerebrovascular diseases in type 2 diabetic patients: the Verona Diabetes Study. Cerebrovasc Dis 23 (2006) 20-26
26. Shoji T., Emoto M., Shinohara K., Kakiya R., Tsujimoto Y., Kishimoto H., Ishimura E., Tabata T., and Nishizawa Y. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12 (2001) 2117-2124
27. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., and London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
28. Asmar R.G., London G.M., O'Rourke M.E., and Safar M.E. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 38 (2001) 922-926
29. London G.M., Asmar R.G., O'Rourke M.F., and Safar M.E. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 43 (2004) 92-99
30. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D., Hughes A.D., Thurston H., and O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225